Found: 47
Select item for more details and to access through your institution.
Analytical and clinical validation of PATHWAY Anti-HER-2/neu (4B5) antibody to assess HER2-low status for trastuzumab deruxtecan treatment in breast cancer.
- Published in:
- Virchows Archiv: European Journal of Pathology, 2024, v. 484, n. 6, p. 1005, doi. 10.1007/s00428-023-03671-x
- By:
- Publication type:
- Article
Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors.
- Published in:
- 2016
- By:
- Publication type:
- journal article
A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Intravenous Bisphosphonate Therapy Does Not Acutely Alter Nuclear Bone Scan Results.
- Published in:
- Clinical Breast Cancer, 2010, v. 10, n. 1, p. 33, doi. 10.3816/CBC.2010.n.004
- By:
- Publication type:
- Article
Assessment of Quality of Life and Treatment Outcomes of Patients With Persistent Postchemotherapy Alopecia.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2–expressing salivary gland carcinoma: a pooled analysis of two phase I studies.
- Published in:
- Japanese Journal of Clinical Oncology, 2024, v. 54, n. 4, p. 434, doi. 10.1093/jjco/hyad181
- By:
- Publication type:
- Article
The cancer patient with chronic pain due to herpes zoster.
- Published in:
- Current Pain & Headache Reports, 2000, v. 4, n. 6, p. 429, doi. 10.1007/s11916-000-0066-7
- By:
- Publication type:
- Article
Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients.
- Published in:
- Breast Cancer Research & Treatment, 2024, v. 203, n. 2, p. 271, doi. 10.1007/s10549-023-07143-3
- By:
- Publication type:
- Article
Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: a feasibility study.
- Published in:
- Breast Cancer Research & Treatment, 2022, v. 195, n. 3, p. 341, doi. 10.1007/s10549-022-06669-2
- By:
- Publication type:
- Article
Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2020, v. 183, n. 1, p. 227, doi. 10.1007/s10549-020-05726-y
- By:
- Publication type:
- Article
HER2 breast cancer therapies: a review.
- Published in:
- Biologics: Targets & Therapy, 2009, v. 3, p. 289
- By:
- Publication type:
- Article
Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm.
- Published in:
- Therapeutic Advances in Medical Oncology, 2023, p. 1, doi. 10.1177/17588359231175440
- By:
- Publication type:
- Article
The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
- Published in:
- Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2015, v. 22, p. 495, doi. 10.1245/s10434-015-4697-7
- By:
- Publication type:
- Article
Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-39241-7
- By:
- Publication type:
- Article
Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-39241-7
- By:
- Publication type:
- Article
Managed Care Considerations in the Treatment of HER2-Positive Advanced Breast Cancer: A Closer Look at Recent Advances for Improved Patient Outcomes.
- Published in:
- Journal of Managed Care Medicine, 2024, v. 27, n. 2, p. 40
- By:
- Publication type:
- Article
Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Timing of exercise therapy when initiating adjuvant chemotherapy for breast cancer: a randomized trial.
- Published in:
- European Heart Journal, 2023, v. 44, n. 46, p. 4878, doi. 10.1093/eurheartj/ehad085
- By:
- Publication type:
- Article
An update on epidermal growth factor receptor inhibitors.
- Published in:
- Current Oncology Reports, 2002, v. 4, n. 1, p. 47, doi. 10.1007/s11912-002-0047-6
- By:
- Publication type:
- Article
Chapter 2: Anti-HER2/neu Therapy for Metastatic Breast Cancer.
- Published in:
- 2008
- By:
- Publication type:
- Book Chapter
Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/− trastuzumab in patients with breast cancer brain metastases.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00404-2
- By:
- Publication type:
- Article
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00380-7
- By:
- Publication type:
- Article
A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Biomonitoring of urinary tamoxifen and its metabolites from breast cancer patients using nonaqueous capillary electrophoresis with electrospray mass spectrometry.
- Published in:
- Electrophoresis, 2001, v. 22, n. 13, p. 2730, doi. 10.1002/1522-2683(200108)22:13<2730::AID-ELPS2730>3.0.CO;2-3
- By:
- Publication type:
- Article
Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series.
- Published in:
- 2014
- By:
- Publication type:
- Report
A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2013, v. 139, n. 1, p. 107, doi. 10.1007/s10549-013-2510-5
- By:
- Publication type:
- Article
A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2005, v. 90, n. 2, p. 157, doi. 10.1007/s10549-004-3974-0
- By:
- Publication type:
- Article
Department of Genetics University of North Carolina Chapel Hill.
- Published in:
- 2008
- By:
- Publication type:
- Letter
Preoperative chemotherapy for breast cancer: miracle or mirage?
- Published in:
- 2007
- By:
- Publication type:
- journal article
Preoperative Chemotherapy for Breast Cancer.
- Published in:
- 2007
- By:
- Publication type:
- Editorial
Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Incidence of chemotherapy‐induced, long‐term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane.
- Published in:
- Cancer (0008543X), 2005, v. 104, n. 8, p. 1575
- By:
- Publication type:
- Article
Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: A Phase 2 Clinical Trial.
- Published in:
- JAMA Network Open, 2019, v. 2, n. 11, p. e1916211, doi. 10.1001/jamanetworkopen.2019.16211
- By:
- Publication type:
- Article
First-in-Human Evaluation of Site-Specifically Labeled <sup>89</sup>Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 8, p. 1, doi. 10.2967/jnumed.123.266392
- By:
- Publication type:
- Article
First-in-Human Evaluation of Site-Specifically Labeled <sup>89</sup>Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 3, p. 386, doi. 10.2967/jnumed.123.266392
- By:
- Publication type:
- Article
First-in-Human Evaluation of Site-Specifically Labeled <sup>89</sup>Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 2, p. 1, doi. 10.2967/jnumed.123.266392
- By:
- Publication type:
- Article
Clinical Implications of Pathophysiological and Demographic Covariates on the Population Pharmacokinetics of Trastuzumab Emtansine, a HER2-Targeted Antibody-Drug Conjugate, in Patients With HER2-Positive Metastatic Breast Cancer.
- Published in:
- Journal of Clinical Pharmacology, 2012, v. 52, n. 5, p. 691, doi. 10.1177/0091270011403742
- By:
- Publication type:
- Article
A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer.
- Published in:
- Cancer (0008543X), 2012, v. 118, n. 23, p. 5733, doi. 10.1002/cncr.27622
- By:
- Publication type:
- Article
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer.
- Published in:
- NPJ Breast Cancer, 2024, v. 10, n. 1, p. 1, doi. 10.1038/s41523-024-00699-3
- By:
- Publication type:
- Article
Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00592-5
- By:
- Publication type:
- Article
Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5‐Year Follow‐up.
- Published in:
- Oncologist, 2019, v. 24, n. 8, p. e646, doi. 10.1634/theoncologist.2018-0512
- By:
- Publication type:
- Article
Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience.
- Published in:
- Oncologist, 2017, v. 22, n. 2, p. 139, doi. 10.1634/theoncologist.2016-0268
- By:
- Publication type:
- Article
Ganetespib: research and clinical development.
- Published in:
- OncoTargets & Therapy, 2015, v. 8, p. 1849, doi. 10.2147/OTT.S65804
- By:
- Publication type:
- Article
Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies.
- Published in:
- CA: A Cancer Journal for Clinicians, 2022, v. 72, n. 2, p. 165, doi. 10.3322/caac.21705
- By:
- Publication type:
- Article
Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study.
- Published in:
- Breast Cancer (13406868), 2024, v. 31, n. 5, p. 858, doi. 10.1007/s12282-024-01600-7
- By:
- Publication type:
- Article